Moomoo AI 已提取核心信息
Adial Pharmaceuticals, Inc. has announced a prospectus for the potential offering of up to $100,000,000 in securities, which may include common stock, preferred stock, debt securities, warrants, or units. The securities may be offered from time to time in various transactions at fixed prices, prevailing market prices, or negotiated prices. The specific terms of any offering, such as the names of underwriters, dealers, or agents, purchase price, and net proceeds, will be detailed in future prospectus supplements. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of January 19, 2024, the last reported sale price of Adial's common stock was $1.275 per share. The company has not sold any shares of common stock under General Instruction I.B.6 to Form S-3 in the twelve months preceding the date of the prospectus. Investing in the securities involves risks, which are detailed under the heading 'Risk Factors' in the prospectus.
Adial Pharmaceuticals, Inc. has announced a prospectus for the potential offering of up to $100,000,000 in securities, which may include common stock, preferred stock, debt securities, warrants, or units. The securities may be offered from time to time in various transactions at fixed prices, prevailing market prices, or negotiated prices. The specific terms of any offering, such as the names of underwriters, dealers, or agents, purchase price, and net proceeds, will be detailed in future prospectus supplements. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of January 19, 2024, the last reported sale price of Adial's common stock was $1.275 per share. The company has not sold any shares of common stock under General Instruction I.B.6 to Form S-3 in the twelve months preceding the date of the prospectus. Investing in the securities involves risks, which are detailed under the heading 'Risk Factors' in the prospectus.
Adial Pharmicals, Inc.已经宣布了可能发行高达1亿美元的证券的招股说明书，其中可能包括普通股、优先股、债务证券、认股权证或单位。证券可以不时地以固定价格、现行市场价格或协议价格以各种交易形式发行。任何发行的具体条款，例如承销商、交易商或代理商的名称、收购价格和净收益，将在未来的招股说明书补充文件中详细说明。该公司的普通股在纳斯达克资本市场上市，股票代码为 “ADIL”。截至2024年1月19日，阿迪亚尔上次公布的普通股销售价格为每股1.275美元。在招股说明书发布之日前的十二个月中，该公司没有根据一般指令I.B.6向S-3出售任何普通股。投资证券涉及风险，在招股说明书的 “风险因素” 标题下详细介绍了这些风险。
Adial Pharmicals, Inc.已经宣布了可能发行高达1亿美元的证券的招股说明书，其中可能包括普通股、优先股、债务证券、认股权证或单位。证券可以不时地以固定价格、现行市场价格或协议价格以各种交易形式发行。任何发行的具体条款，例如承销商、交易商或代理商的名称、收购价格和净收益，将在未来的招股说明书补充文件中详细说明。该公司的普通股在纳斯达克资本市场上市，股票代码为 “ADIL”。截至2024年1月19日，阿迪亚尔上次公布的普通股销售价格为每股1.275美元。在招股说明书发布之日前的十二个月中，该公司没有根据一般指令I.B.6向S-3出售任何普通股。投资证券涉及风险，在招股说明书的 “风险因素” 标题下详细介绍了这些风险。
有用
没用
